Clinical Trial

Neurodegenerative Diseases Clinical Trial 20203243

[LCID Study Number: 20203243]

Cutaneous Phosphorlyated a-synuclein Detection as a Biomarker of Synucleinopathy (Synuclein-One)

The purpose of this study is to define the role of phosphorylated alphasynuclein pathology in the diagnosis of synucleinopathies through qualitative and quantitative measurements of cutaneous phosphorylated alpha-synuclein in patients with Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies and pure autonomic failure.

Disease/Condition: Neurodegenerative Diseases

Department: Gastroenterology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email:

Primary Contact Phone: 781-744-2400

Clinical Trial Details

View NCT ID 04700722 on

Protocol #: 20203243

Principal Investigator(s): Oleg Y. Yerstein

Study Coordinator(s): Tanya Fennell

Trial Phase: Sponsor Initiated Study Observational